share_log

Citigroup Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84

Benzinga ·  May 23 13:27

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $89 to $84.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment